

## Subject Index to Volume 7 (1990)

- 1-(beta-D-glucopyranosyl)phenobarbital, 402  
1-dodecylazacycloheptan-2-one, penetration enhancer, 64  
1-farnesylazacycloheptan-2-one, penetration enhancer, 64  
1-geranylazacycloheptan-2-one, penetration enhancer, 64  
1-vinyl-2-pyrrolidinone, hydrogels, 816  
2-arylpropionic acids, chiral HPLC assay, 1262  
2D-NMR techniques, metabolism arteether, 199  
3-arylmethyl 5-isopropyl 1,4-dihydro-2,6-dimethyl-4-(pyridinedi-carboxylates), 919  
3 alpha-hydroxydeoxyarteether, 199  
3 alpha-hydroxydeoxydihydroarteemisinin, 199  
3H-SCH 23390, 280  
3H-spiroperone, 280  
4-biphenyl acetic acid, antiinflammatory ointment, 1152  
4-cyanophenol, skin penetration, 835  
4-hydroxy-2,6-xylylidine, quantification of, 504  
5-fluorouracil, prodrugs, cytotoxicity L1210 cells, 1294  
7-[3-(4-[2,3-dimethylphenyl]piperazinyl)propoxyl-2(1H)-quinolone, 280  
9-amino-1,2,3,4-tetrahydroacridine, brain targeted delivery, 658  
10 alpha-hydroxymorphine, 1205  
1,3-dioxolanes, 746  
1,4-dihydropyridine derivatives, 919  
16 alpha-hydroxy-( $\gamma$ )kauranoic acid, 376  
17 beta-estradiol, nasal absorption, 500  
3,4-dihydroxyphenylacetic acid (DOPAC), amantadine, 670
- absorption enhancement, insulin rectal, 180  
absorption enhancer, human growth hormone, 547  
absorption enhancer, nasal, 808  
absorption enhancer, nasal, growth hormone, 772  
absorption kinetics, 59  
absorption promoters of peptides, 127  
absorption rate constant, apparent zero order, 76  
absorption rate, 677  
absorption, remoxipride, 54  
absorption, cyclodextrins, 1248  
ACC-9653, 1172  
acetaminophen in plasma, 204  
acetylcholine, muscarinic, QSAR, 746  
acetylcholinesterases, gene amplification, 1  
acrylate methacrylate coacervates, 1208  
ACTH, deamidation, 593  
activation energies, aspirin, 730  
activity assay, human renin, inhibitory peptides, 407  
acyclovir, intestinal uptake mechanism, in vitro, 299  
acyclovir, percutaneous absorption, 64  
acyl glucuronide, tolmetin, 21  
acyl migration, tolmetin, 21  
adenocarcinoma, Caco-2 cell transport, 902  
adenocarcinoma, metastatic, chimeric antibody, 587  
adenosine deaminase inhibitor, pentostatin, 452  
adenosine triphosphate, liposomes, 553  
adjuvants, aluminum compounds, 1282  
adrenergic receptors, 1213  
adrenocorticotrophic hormone, deamidation, 593  
aerosol, fluorescein, 8  
aerosols, 1228  
aerosols, leuprolide, 565  
aerosols, liposomes dispersions, 1127  
aerosols, lung absorption, rat, 990  
angiotensin I, serum, 407  
AIDS therapy, AZT and probenecid combination, 411  
albumin, iontophoresis, 218  
albumin, irreversible binding to tolmetin, 21  
albumin, human serum, controlled release, 1190  
albumin-cross-linked hydrogels, 816  
aldose reductase inhibitor, 1198  
aldose reductase inhibitor, imirestat, 192  
aliphatic acids, transepithelial transport, 325  
alkyl para-aminobenzoates, heat capacities, 1157  
alpha-2 adrenergic receptor, 208  
alpha-adrenoceptor agonists, 508  
alpha-lactose monohydrate, compaction, 113  
alpha-methyl-dopa-phe absorption, 308  
aluminum compounds, adjuvants vaccines, 1282  
aluminum hydroxide, vaccine adjuvant, 1282  
aluminum hydroxyphosphate, vaccine adjuvant, 1282  
Alzheimer's disease, 9-amino-1,2,3,4-tetrahydroacridine, 658  
amantadine, effect on dopaminergic neurons, 670  
amastatin, peptidase inhibitors, 1099  
amino acid carrier, L-alpha-methyl-dopa, 1313  
amobarbital N-glucosides, diastereomers, 794  
amobarbital N-glucosides, stereochemical characterization, 794  
amorphous polymer, PVP, 654  
amorphous sucrose, 1278  
amorphous-crystalline transformation of sucrose, 1278  
amoxicillin, pharmacokinetics middle ear, 1242  
anesthesia, gentamicin pharmacokinetics, rat, 41  
angiotensin converting enzyme inhibitor, moexipril, 379  
*annona bullata*, diterpene, 376  
anterior pituitary, growth hormone release, 1011  
antibody, chimeric, pharmacokinetics, 587  
antiendotoxin, lipid A, 260  
antiendotoxin, lipid X, 260  
antifungal agents, reduction potentials, 283  
antihepatotoxin, effect against microcystin-LR toxicity, 256  
antiinflammatory ointment, 1152  
antiinflammatory, ethyl 4-biphenyl acetate in ointment, 1152  
antimalarial arteether, metabolism, 923  
antimalarial drug, arteether, 199  
antiprotozoal agent GGP-291 metabolism, 742  
antipyrene metabolism, 204  
antiulcer agent, cimetidine, 665  
apomorphine, pharmacodynamics, pharmacokinetics, 318  
area function analysis, 76  
arecoline, skin permeation, 1201  
Arrhenius equation, heat sterilization, 1273  
arteether metabolism, 923  
arteether microbial metabolism, 199  
artemisinin derivatives, 199  
asialofetuin, liposome targeting, 542  
asialofetuin-labeled liposomes, 542  
asparaginyl deamidation, 703  
asparaginyl residues, deamidation, 787  
asparaginyl, 787  
aspartyl stability, 703  
aspartyl, 787  
aspirin hydrolysis, 730  
aspirin, effect on sulfate homeostasis, 719  
association, chlorpromazine, 856  
atom index, 801  
autoradiography, quantitative whole body, 935  
azidothymidine (AZT), 948  
azidothymidine, iontophoresis, 34  
azone metabolism, species differences, 496  
azone, penetration enhancer, 64  
azone, penetration enhancer, 496  
azone, skin penetration, 1042

- Beauvaria bassiana*, model of mammalian metabolism, 742  
 benoxaprofen, chiral HPLC assay, 1262  
 benzene-*p*-diphosphate, 600  
 benzene-*p*-disulfonate, test binding to insulin, 600  
 benzocaine diffusion, 523  
 benzocaine solubility, 523  
 benzocaine, percutaneous absorption, 1147  
 benzodiazepines, binding to casein, 633  
 benzoic acid, percutaneous absorption, 352  
 benzoic acid, percutaneous absorption, 1147  
 benzoic acid, percutaneous absorption, human skin, 230  
 beta-blocker nadolol, 953  
 beta-blocker prodrugs, 723  
 beta-blocker, pafenolol, 1222  
 beta-cyclodextrin derivatives antiinflammatory ointment, 1152  
 beta-cyclodextrin, pharmacokinetics, 1248  
 beta-cyclodextrin/steroid complexation, 869  
 bile salt, permeation enhancer, 468  
 bile salts, ciliostasis, 144  
 biliary elimination, ibuprofen, 87  
 biliary excretion profile, bismuth, 237  
 biliary excretion, methylergometrine, 14  
 binding of drugs in milk, 537  
 binding site, lung, monoamine oxidase, 398  
 bioactivation, sequential enzymatic, 723  
 bioadhesion hydroxypropylmethacrylate, nanoparticles, 49  
 bioadhesion mucin-biopolymer, 491  
 bioavailability human growth hormone, 547  
 bioavailability, hydralazine, 274  
 bioavailability, ibuprofen, 304  
 bioavailability, L-dopa, L-dopa esters, 384  
 bioavailability, lithium carbonate, 359  
 bioavailability, mycophenolic acid, 161  
 bioavailability, nasal albumin, 69  
 bioavailability, triamcinolone diacetate, 558  
 bioavailability, triamcinolone tablets, 558  
 bioindicator, heat sterilization, 1273  
 bismuth binding, serum albumin, plasma, 188  
 bismuth excretion profile, rat, 237  
 bismuth, pharmacokinetics, rat, 237  
 bismuth, rat, 188  
 blister fluid, fleroxacin, 422  
 blood-brain barrier (BBB), DGAVP, 293  
 blood-brain barrier, 1061  
 blood-brain barrier, estradiol prodrug, 1107  
 blood-brain barrier, estradiol, 879  
 boehmite, vaccine adjuvant, 1282  
 boiling point, 942  
 brain enhanced drug delivery, estradiol, 879  
 brain targeting chemical delivery system, 658  
 brush border membrane, absorption alpha-methyldopa-phe, 308  
 butyrylcholinesterases, gene amplification, 1  
  
 Caco-2 cell monolayers, L-alpha-methyldopa transport, 1313  
 Caco-2 cell, 902  
 calcium salt, tablet filler, 80  
 calcium-channel antagonists, 919  
 calorimetry, differential scanning, 1157  
 calorimetry, insulin, 606  
 calorimetry, misoprostol films, 1181  
 captopril, chirality, 1082  
 captopril, circular dichroism, 1082  
 captopril, diastereomers, 1082  
 captopril, uv absorption, 1082  
 carbamazepine dihydrate, 184  
 carbamazepine, anhydrous, 184  
 carbamazepine, disposition in rats, 513  
 carbamazepine-10,11-epoxide, disposition in rats, 513  
 carboxy inulin, iontophoresis, 218  
 carboxyfluorescein, liposomes, 1127  
 carboxy inulin blood clearance, rat, 41  
 carboxylic ester hydrolase activity, 251  
 carboxymethyltransferase, 593  
 carboxyprimaquine, 91  
  
 caries, local drug release, 313  
 carrier mediated transport, cefpiramide, 1038  
 casein, role in milk protein binding, 633  
 cefaclor dihydrate <sup>13</sup>C solid state NMR, 147  
 cefaclor dihydrate, crystal structure, 147  
 cefpiramide, hepatic uptake, 1038  
 cell cultures, endothelial, epithelial, 435  
 cellulose, hydroxypropyl methyl, film, 1181  
 cerebrospinal fluid distribution, zidovudine, 332  
 charcoal, effect on phenobarbital hypnosis, 242  
 charcoal, effect on theophylline neurotoxicity, 242  
 chemical delivery system, 9-amino-1,2,3,4-tetrahydroacridine, 658  
 chemical delivery system, estradiol, 1061  
 chemical delivery system, estradiol, growth hormone, 1011  
 chemical stability, pentostatin, 452  
 chemometric assay validation, 154  
 chimeric mouse/human monoclonal antibody, C-17-1A, 587  
 chiral derivatization, 1262  
 chirality, captopril, 1082  
 chitosan-methotrexate (CMTX) macromolecular conjugate, 418  
 chlorhexidine phosphanilate creams, 995  
 chlorhexidine, sustained release, 313  
 chlorhexidine-phosphanilate, skin permeation, 995  
 chlorpromazine, partition coefficients, 856  
 cholinergic receptors, developments, 562  
 cholinesterases, 1  
 ciliotoxicity, 144  
 ciprofloxacin, HPLC, 1177  
 circular dichroism, captopril, 1082  
 circular hole matrix release, 1195  
 clearance of carbamazepine-10,11-epoxide, 513  
 clinical pharmacokinetics, 681  
 clozapine, pharmacokinetics, 347  
 clozapine, psychiatric patients, 347  
 coating hot melt, 1119  
 colon model, rabbit, 616  
 column-switching HPLC, hydrochlorothiazide, 1257  
 compactibility, binary powder systems, 113  
 compensation temperature, 730  
 complexation, steroid-beta-cyclodextrin, 869  
 conductivity, 893  
 conjugates lidocaine, 504  
 container compatibility, 967  
 container-solute interaction, 967  
 content uniformity, tablets, 962  
 controlled release, diltiazem, dog, 874  
 controlled release, matrix tablet, 1092  
 controlled release, nanoparticles, 49  
 controlled release, remoxipride, 54  
 controlled release, theophylline, 1134  
 convective flow, transdermal, 34  
 cortisol, beta-cyclodextrin complex, 869  
 cosolvent, benzocaine solubility, 523  
 cotton seed oil, hot melt coating, 1119  
 creep compliance technique, 648  
 crystal structure, cefaclor dihydrate, 147  
 crystalline sucrose, 1278  
 crytallography, 683  
*cunninghamella blakesleeana*, retinoic acid metabolism, 270  
*cunninghamella echinulata*, retinoic acid metabolism, 270  
 current voltage characteristics, fresh, frozen skin, 1141  
 current-voltage characteristics, human skin, 136  
 cutaneous first pass, 638  
 cutaneous metabolism, 638  
 cyanoacrylate, nanoparticles, 736  
 cyclic imide, deamidation Asn residues, 787  
 cyclic imide, peptide degradation, 703  
 cyclodextrin, dimethyl-beta-, nasal absorption, 500  
 cyclodextrine derivatives, indomethacin stability, 484  
 cyclodextrines, indomethacin stability, 484  
 cyclodextrins derivatives, 612  
 cyclosporine clearance, dietary fat, 46  
 cyoctol, cutaneous metabolism, 638  
 cyoctol, metabolic conversion, 638

- cytoplasmic delivery, 824  
cytotoxic agent, pentostatin, 452  
cytotoxicity, fluoropyrimidines, 1294  
cytotoxicity, primaquine, 91  
cytotoxicity assay, B lymphoblastoid cells, 852
- deamidation asparaginyl residue, 703  
deamidation peptides, 530  
deamidation, aspartyl, asparaginyl, ACTH, 593  
deamidation, peptides, 787  
decomposition, monoclonal antibodies, 1234  
degradation, thyrotropin releasing hormone, 751  
desglycinamide-arginine vasopressin (DGA VP, AVPI-8), pharmacokinetics, 293  
desglycinamide-arginine vasopressin, 293  
desipramine, tissue distribution, 1019  
deuterium isotope effect primaquine, 91  
dextran sulfate, effect on renal gentamicin accumulation, 644  
diastereomers captorpiil, 1082  
diastereomers phenobarbital N-beta-D-glucose conjugate, 402  
diastereomers, 683  
diclofenac sodium absorption, 1026  
dictionary of drug names, 780  
dietary fat, carrier, cyclosporine, 46  
dietary fat, cyclosporine clearance, 46  
diffusion cells, topical drug delivery, 1048  
diffusion controlled matrix, 1195  
diffusion, drug dissolution, 425  
diffusion, porous materials, 893  
difloxacin, HPLC, 1177  
dihydropyridine-pyridinium salt, prodrug, 879  
dihydroreynosin glucoside, 1269  
dihydrotamulipin A glucoside, 1269  
diltiazem for mutations, 874  
diltiazem, controlled release, 874  
dimethyl-beta-cyclodextrin, nasal absorption, 500  
dimyristoyl-phosphatidylcholine, liposomes, solubilization, 957  
dipeptide, intestinal absorption, 308  
diphtheria toxin A chain (DTA) liposomes, 824  
disperse systems, 561  
dissolution boundary, 1195  
dissolution modeling, 425  
dissolution rates, tablet filler, 80  
dissolution USP standards, 983  
dissolution, theophylline, in vitro, 1134  
distribution coefficient, snake skin, 1302  
distribution of nonionized drug, in tissue, 691  
diterpene, *annona bullate*, 376  
dithioerythritol, antihepatotoxin, 256  
diuretic effect, hydrochlorothiazide-furosemide combination, 697  
diuretics, therapeutic index, 697  
diurnal variation, pharmacokinetics, 677  
DNA amplification in vivo, 1  
dog animal model, hydralazine, 274  
dopamine receptors, pre- and post-synaptic, 280  
dopaminergic neurons, effect of amantadine, 670  
dosage forms, 562  
dose dependent pharmacokinetics of carbamazepine, 513  
dose regimen, single vs multiple, clozapine, 347  
dosing frequency, 677  
drug absorption, gastrointestinal, 518  
drug delivery, chitosan-methotrexate, 418  
drug delivery, pH sensitive liposomes, 824  
drug design, computer aided, 784  
drug protein binding determination, 1077  
drug release, USP standards, 983  
drug solubilizations, skin permeation, 712  
drug targeting, adenosine triphosphate, 553  
drug therapy, simple techniques, 681  
duodenal pH, in young adults, 756  
DuP 923, 4-hydroxy-N-phenyl-3,5-bis(1-pyrrolidine methyl)benzamide dihydrochloride, 1325  
DuP 923, antiarrhythmic agent, 1325  
DuP 923, ionization, 1325  
DuP 923, solubility, 1325
- E- $\Delta$  <sup>2</sup>-valproic acid, binding to rat plasma, 461  
Elaphe Obsoleta, black rat snake, 1302  
*elaphe obsoleta*, shed snake skin, 1042  
electrochemistry, antifungal agents, 282  
electrolytes, 719  
electroosmosis, mouse skin, 213, 222  
electroosmotic flow, 118  
electrotopological state, 801  
emulsion polymerization, vidarabine, 736  
enantiomers methylphenidate, 726  
enantiomorphic crystals, 683  
enantioselectivity, amobarbital, 794  
endothelial cell culture, 435  
endotoxin, 260  
enhancer fatty acid, skin permeation, 712  
enkephalin metabolism, skin, 1099  
enteric coating, 648  
enteric-coated tablet, radiotelemetric technique, 1026  
enterohepatic cycling, ibuprofen, 87  
enterohepatic recirculation, methylergometrine rat, 14  
enzymatic degradation TRH, stability plasma, 751  
enzymatic hydrolysis, TRH, 885  
enzyme inhibitors, hydrolase inhibitors, 249  
enzyme-digestible hydrogels, 816  
epicardial drug administration, lidocaine, 28  
epidermal differentiation, fetal skin, 1201  
epidermal growth factor (EGF), receptors, 665  
epidermal growth factor, wound healing, 1289  
epimerization, moxalactam, 364  
episodic hormone secretion, pituitary, 1011  
epithelial cell culture, 435  
epithelial tissue culture, transport, 902  
erbium-171, 263  
erosion mechanisms, 431  
error correction technique, chemometric approach, 154  
erythrocytes, pyrimethamine, 1055  
erythromycin beads, 264  
erythromycin dissolution, 264  
ester derivatization, mycophenolic acid, 161  
ester prodrugs, zidovudine skin permeation, 948  
estradiol absorption, human skin, 170  
estradiol delivery system, brain, 1107  
estradiol, chemical delivery system, 1011, 1061  
estradiol, delivery to brain, 879  
ethanol, estradiol absorption, skin, 170  
ethyl 4-biphenyl acetate, antiinflammatory ointment, 1152  
europium, chiral, nmr shift reagent, 726  
everted sac technique, intestinal transport, 767  
excipient incompatibility, moexipril, 379  
experimental drugs, 988  
extreme vertices, 1092
- fasted state pH, in young adults, 756  
fatty acids unsaturated nasal absorption enhancer, 127  
FDA, IND, 988  
fed state pH, in young adults, 756  
fentanyl, transdermal delivery, 842  
film, hydroxypropyl methylcellulose, 1181  
first-pass metabolism, 59  
fleroxacin, tissue concentrations, 422  
flunoxaprofen, chiral HPLC assay, 1262  
fluorescein absorption, rat lung, 8  
fluorescein, aerosol, 8  
fluorescent chiral amines, 1262  
fluorescent probes, liposomes, 824  
fluoride, sustained-release, 313  
fluorine-18, 1198  
fluoropyrimidines, cytotoxicity, 1294  
food effect ibuprofen absorption, 304  
food effect, theophylline, 1134  
food effects on gastrointestinal pH, 756

- food-drug interaction, hydralazine, 274  
 Fourier transform, i.r., 762  
 freeze-drying, ribonuclease A stability, 1086  
 front synchronization, 431  
 frozen plasma, urine, moxalactam 364  
 ftorafur, 1294  
 fungicides, 283  
 furosemide, pharmacodynamics, 697  
 fusidic acid, 468
- G** protein coupled receptors, 1213  
 gabexate mesilate, wound healing, 1289  
 gamma scintigraphy, g.i. transit, 54  
 gamma scintigraphy, eribum-171, 264  
 ganciclovir HPLC, plasma, urine, rabbit, 1113  
 gastric mucosa, EGF receptor, 665  
 gastric pH in young adults, 756  
 gastrointestinal absorption, gastrointestinal fluids, 518  
 gastrointestinal absorption, pafenolol, 1222  
 gastrointestinal fluids, volume/flow ratio, 518  
 gastrointestinal irritation by drugs, 616  
 gastrointestinal therapeutic system (GITS), 616  
 gastrointestinal transit <sup>111</sup>In-marked spheres, 54  
 gastrointestinal transit, ibuprofen, 304  
 gastrointestinal transit, nondisintegrating, 1163  
 gastrointestinal transit, sustained release ibuprofen, 304  
 gel integrity, 816  
 gelatin, wound healing, 1289  
 gender effects, gastric pH, 756  
 gene amplification, cholinesterases, 1  
 gentamicin pharmacokinetics, rat anesthetized, 41  
 gentamicin, renal accumulation, 644  
 gestation, fetal skin, 1201  
 GGP-291 metabolism, 742  
 glass transition temperature, PVP, 654  
 glaucoma, drug delivery, 723  
 glucose, iontophoresis, 222  
 glucuronide, tolmetin, 21  
 glycine, iontophoresis, 222  
 glycyL-2,6-xylylide, quantification of, 504  
 gonadorelin, stability, 1253  
 gonatropins, E2-CDS effect on, 1107  
 granulation acrylate, 1208  
 growth hormone (hGH), intranasal, 772  
 growth hormone, estradiol chemical delivery system, 1011
- hairless guinea pig, percutaneous absorption, 1147  
 heart rate, apomorphine, 318  
 heat capacity, alkyl para-aminobenzoates, 1157  
 heat sterilization, thermodynamic data, 1273  
 Heidelberg capsule, in pigs, 1163  
 hepatic uptake, cefpiramide, 1038  
 hepatic uptake, macromolecules, 339  
 hepatocytes, interferon-gamma uptake, 542  
 hepatocytes, rat, 256  
 hepatocytes, transport of cefpiramide, 1038  
 hepatotoxin, 256  
 histidyl-proline amide, stability plasma, 751  
 HMG-CoA, reductase inhibitors, 289  
 homovanillic acid (HVA), amantidine, 670  
 hormone receptors, 1213  
 HPLC ganciclovir, 1113  
 HPLC lipophilicity screen, 577  
 HPLC phenylpropanolamine, urine, blood, 96  
 HPLC pyrimethamine, 1055  
 HPLC, ciprofloxacin, 1177  
 HPLC, column switching, hydrochlorothiazide, 1257  
 HPLC, difloxacin, 1177  
 HPLC, hydroxypropyl-beta-cyclodextrin, 1248  
 HPLC, nadolol, 953  
 HPLC, norfloxacin, 1177  
 HPLC, sarafloxacin, 1177  
 HPLC, temafloxacin, 1177  
 HPLC-MS, peptide RS-26306, 530  
 HPMA nanoparticles, mucoadhesion, 49  
 human growth hormone, nasal administration, 547  
 hydralazine pharmacokinetics, dog, 274  
 hydrochlorothiazide determination, HPLC, 1257  
 hydrochlorothiazide, pharmacodynamics, 697  
 hydrocortisone, beta-cyclodextrin complex, 869  
 hydrogel enzyme digestible, 816  
 hydrolase carboxylic ester, 251  
 hydrophilic permeants, 621  
 hydrophobic effect, chlorpromazine, 856  
 hydrophobic interactions, muscarinic receptors, 746  
 hydroxypropyl methyl cellulose (HPMC), 1186  
 hydroxypropyl methylcellulose phthalate, dissolution, 648  
 hydroxypropyl methylcellulose, miscibility with misoprostol, 1181  
 hydroxypropyl-beta-cyclodextrin, pharmacokinetics, 1248  
 hydroxypropylcyclodextrin, 612  
 hydroxypropylmethacrylate mucoadhesion, in vitro, 49  
 hypoglycemic effect, nasal insulin, 370
- i.r. analysis, 762  
 ibuprofen biliary elimination, rats, 87  
 ibuprofen enterohepatic circulation, rats, 87  
 ibuprofen metabolites, 87  
 ibuprofen sustained release, 304  
 icebergs, hydrophobic group associated, 730  
 iminium, antifungal agents, 283  
 imipramine, tissue distribution, 1019  
 imirestat 18F, scintigraphy, 1198  
 imirestat pharmacokinetics, rats, dogs, 192  
 immunization, sulfanilic acid conjugate, 767  
 immunosuppressant agent, pentostatin, 452  
 in vitro-in vivo correlation, theophylline, 1167  
 in vitro-in vivo correlations, rolipram transdermal, 1302  
 incompatibility screen, moexipril excipient, 379  
 IND, 988  
 indomethacin stability, 484  
 inertial testing methods, 1228  
 infrared spectroscopy, skin penetration, 835  
 infrared spectroscopy, skin permeation, 762  
 inhalation, aerosols, 1228  
 inhibitors, proteinases, 430  
 insulin binding to phenols, 606  
 insulin hexamer-stabilizing ligands, 600, 606  
 insulin, nasal absorption, 370  
 insulin, rectal absorption enhancement, 180  
 interferon-gamma, hepatocyte uptake, 542  
 interferon-gamma, liposome encapsulation, 542  
 intestinal absorption, 852  
 intestinal absorption, acyclovir, 299  
 intestinal absorption, effect of taurocholate, 392  
 intestinal drug transport, in vitro model, 902  
 intestinal loop, hydrophilic/lipophilic drugs, 392  
 intestinal mucosa, drug transport, 902  
 intestinal transport mechanism, L-alpha-methyldopa, 1313  
 intranasal delivery, human, 69  
 ion pairing, chlorpromazine, 856  
 ion pairing, skin permeation, 712  
 iontophoresis, 213, 222  
 iontophoresis, azidothymidine, rat skin, 34  
 iontophoresis, fresh human skin, 1141  
 iontophoresis, human skin, 134  
 iontophoresis, mechanisms, 222  
 iontophoresis, molecular weight dependence, 222  
 iontophoresis, transdermal, 118  
 irreversible binding, tolmetin to albumin, 21  
 isoaspartyl formation, ACTH, 593  
 isoaspartyl stability, 703  
 isoaspartyl, 787  
 isopropyl myristate, penetration enhancer, 1302  
 isopropylmyristate (IPM), zidovudine prodrug, 948  
 isosorbide dinitrate, cutaneous pharmacodynamics, 1298  
 isothermal method, vitamin A, 388

- jejunum acyclovir absorption, 299  
 kyotorphin, nasal absorption, 127  
 L-alpha methyl dopa, intestinal transport, 1313  
 L-dopa esters, oral, rectal administration, 384  
 L1210 cells, cytotoxicity 5-fluorouracil, 1294  
 lactose, tablet filler, 80  
 laser doppler velocimetry, isosorbide dinitrate, 1298  
 latex particles, g.i. absorption, 848  
 laureth-9, ciliostasis, 144  
 laurocapram, 496  
 leuprolide acetate absorption, 565  
 LHRH agonist, 565  
 lidocaine metabolites analysis, 504  
 lidocaine pharmacodynamics, 28  
 lidocaine, epicardial controlled release, 28  
 lidocaine, percutaneous absorption, 1033  
 lipid A analogues, antiendotoxin activity, 260  
 lipid A antiendotoxin, 260  
 lipid phase-separation model, 621  
 lipid X, antiendotoxin, 260  
 lipophilicity basic drugs, 691  
 lipophilicity screen, HPLC, 577  
 lipophilicity, TRH, 885  
 liposome, asialofetuin labeled, 542  
 liposome, model membrane, partitioning, 508  
 liposomes, adenosine triphosphate, 553  
 liposomes, pH sensitive, cytoplasmic delivery, 824  
 liposomes, solubilization, 957  
 lithium carbonate sustained release in vitro, 359  
 Loo-Riegelman method, 76  
 lovastatin, stability testing, 289  
 lung isolated preparation, rat, 990  
 lung mitochondria, binding sites for basic drugs, 398  
 lung, isolated perfused, 398  
 lung, isolated preparation, rat, 8  
 luteinizing hormone-releasing hormone (LH-RH) antagonist stability, 530  
 lymphatic absorption, polar compounds, 169  
 lyophilization protein stability, 1086  
 lyophilized sucrose spheres, 1278  
 lysophosphatidylcholine, nasal, growth hormone, 772  
 M cells, particle absorption, 848  
 macromolecular compounds, tumor bearing mice, 339  
 Madin Darby canine kidney (MDCK) cell monolayer, 325  
 magnoliaceae, cytotoxic activity, 1269  
 malaria, primaquine, 91  
 malnutrition, pharmacokinetics and pharmacodynamics, apomorphine, 318  
 matrix release, 893  
 matrix tablet release, 1092  
 mean metabolic interconversion time, methylprednisone, 1003  
 mean residence time (MRT), metabolite kinetics, 59  
 mean residence time, functions of infusion rate, 628  
 mean residence time, methylprednisone, 1003  
 mean residence times (MRT), reversible metabolism, 103  
 mean transit time, methylprednisone, 1003  
 medicare, 108  
 melanin binding, ocular, 935  
 melting point, 942  
 melting points, 683  
 mephobarbital, optical isomers, 402  
 metabolic profiling, azone, 496  
 metabolism studies, 435  
 metabolism, benzoic acid, 1147  
 metabolite kinetics after oral drug administration, 59  
 metal complexes, antifungal agents, 283  
 metered dose inhaler, 1228  
 metered dose inhaler, terbutaline, 1068  
 metered dose inhalers, 8  
 method validation, chemometric, 154  
 methotrexate-chitosan, conjugates, 418  
 methylergometrine enterohepatic recirculation, 14  
 methylergometrine, pharmacokinetics, rat, 14  
 methylergometrine, protein binding, 14  
 methylphenidate, threo, optical purity, 726  
 methylprednisolone, reversible metabolism, 1003  
 metronidazole, sustained release, 313  
 Michaelis-Menten kinetics, hydralazine, 274  
*Michelia floribunda*, cytotoxic activity, 1269  
 microbial assay, in vitro, 995  
 microbial metabolism, arteether, 199, 923  
 microcalorimetry, insulin, 600, 606  
 microcystin-LR, hepatotoxicity, 256  
 microdialysis sampling, 1077  
 microencapsulation, 928, 1119  
 microspheres, biodegradable, 1190  
 microspheres, drug release, 928  
 migrants in polyethylene terephthalate, 176  
 milk, binding of drugs, 633  
 milk, drug binding, solubility, 537  
 milk, fat content, 537  
 milk, protein binding, 633  
 misoprostol, miscibility with HPMC, 1181  
 misoprostol, stability, 1186  
 mitochondria, lung, drug binding, 398  
 mixed micelles, bile salts, 127  
 mixed micelles, nasal absorption enhancer, 370  
 model cellular transport barrier, 325  
 moexipril, stability, solid state, 379  
 molecular dissymmetry, 683  
 molecular modeling, drug tissue distribution, 935  
 molecular weight cutoff, absorption, 863  
 molecular weight dependent absorption, polyethylene glycols, 863  
 molecular weight, lymphatic absorption, 167  
 molecular weight, transdermal permeability, 1302  
 moment analysis, 76  
 moment analysis, reversible metabolism, 103  
 monoamine oxidase (MAO), 398  
 monoclonal antibodies, fluorescence polarization, 1234  
 monoclonal antibodies, fluorescence quenching, 1234  
 monoclonal antibody, pharmacokinetics, 587  
 morphine, hydroxylated, 1205  
 morphine, hydroxylated, activity in pig ileum, 1205  
 morphine, impurity, 1205  
 moxalactam, epimerization kinetics, 364  
 mucin-polymer bioadhesive, 491  
 mucoadhesion nanoparticles, 49  
 multiparticulate formulations, diltiazem, 874  
 multiple linear regression approach, drug tissue distribution, 935  
 multiple unit capsule, remoxipride, 54  
 muscarinic cholinergic receptors, 1213  
 muscarinic receptor, QSAR, 746  
 mycophenolic acid, bioavailability, 161  
 mydriatic tolerance, 476  
 myocardial infarction, liposomal ATP injection, 553  
*N*-decylmethyl sulfoxide, permeation enhancer, 34  
*n*-decylmethylsulfoxide, penetration enhancer, 1099  
*N*-ethylglycyl-2,6-xylylidide, quantifications of, 504  
*N*-glucoside, amobarbital, 794  
 nadolol, beta blocker, 953  
 nadolol, HPLC, 953  
 nadolol, pharmacokinetics, 953  
 nafamostat mesilate, wound healing, 1289  
 nanoparticle, vidarabine, 736  
 nanoparticles mucoadhesion, 49  
 naproxen, chiral HPLC assay, 1262  
 narcotics, transdermal delivery, 842  
 nasal absorption enhancers, 127  
 nasal absorption enhancers, 808  
 nasal absorption enhancers, toxicity, 144  
 nasal absorption, 17beta-estradiol, 500  
 nasal absorption, 69  
 nasal absorption, growth hormone, 772  
 nasal absorption, kyotorphin, 127

- nasal absorption, mixed micelles, 370  
nasal absorption, polyethylene glycols, 863  
nasal delivery, human growth hormone, 547  
nasal mucosa, surface morphology, 468  
nasal absorption, dimethyl-beta-cyclodextrin, 500  
nebulizers, liposomes, 1127  
neocarcinostatin, protein conjugate, 852  
nephrotoxicity, gentamicin, 644  
nephrotoxicity, in vivo, in vitro, 884  
neurotransmitter receptors, 1213  
neutron activated erbium-171, 264  
neutron activation <sup>171</sup>Er, 304  
neutrophil, 260  
niridazole, metabolism, 742  
Nitro-Dur, transdermal flux, 673  
nitroglycerin (TNG) flux across skin, Yucatan pig, mouse, human, 673  
NMR <sup>13</sup>C solid State, cefaclor dihydrate, 147  
NMR solid state, carbamazepine, 184  
NMR, 2D, arteether, 199  
NMR, insulin, 600  
nondisintegrating oral dosage forms, in pigs, 1163  
nonerodible oral dosage forms, 1163  
nonisothermal method, vitamin A, 388  
nonlinear regression, absorption rate, 76  
nonsteroidal antirheumatic drugs, chiral HPLC assay, 1262  
norfloxacin, HPLC, 1177  
NSAID, ibuprofen, 88  
NSAID, tolmetin, 21  
NSAID, toxicity, 21  
nucleoside, pentostatin stability, 452
- o*-naphthoquinone 5-lipoxygenase, 1071  
*o*-quinone analogues, 1171  
obstructive jaundice, biliary clearance cefpiramide, rats, 1038  
ocular disposition, 1198  
ocular drug delivery, prodrugs, 723  
ocular pharmacodynamics, phenylephrine, 476  
ocular pharmacokinetics, 476  
oily formulation, neocarcinostatin, protein conjugate, 852  
oleic acid, transdermal enhancer, 621, 835  
opioid receptor binding, morphine impurity, 1205  
optical purity, nmr, methylphenidate, 726  
optical purity, threo-methylphenidate, 726  
oral absorption remoxipride, 54  
oral administration, L-dopa, L-dopa esters, 384  
oral dosage form, controlled release, 975  
organophosphorous poisoning, 1  
osmotic formulations, diltiazem, 874  
otitis media, antimicrobial drug penetration, 1242  
ouabain-induced ventricular tachycardia, 28  
oxidative stress, antifungal agents, 283  
oxime hydrolase, prodrug activation, 723  
oxygen polarography, 289
- PABA, percutaneous absorption, 1147  
packaging materials migrants, 176  
pafenolol, pharmacokinetics, 1222  
palmitoleic ester metabolite, 638  
parenteral products, container/solution compatibility, 911  
particle absorption, Peyer's patches, 848  
particle quantitation, 848  
particle size analysis, pressurized inhalers, 1228  
particle size, tablets, 962  
partition coefficient, steroids, 1320  
partition coefficients, chlorpromazine, 856  
partition coefficients, HPLC retention, 577  
partitioning, liposomes, 508  
partitioning, skin permeation, 712  
penetration enhancement, 762  
penetration enhancer, *n*-decylmethyl sulfoxide, 1099  
penetration enhancers, percutaneous, 64  
pentostatin, chemical stability, 452  
pepsin, albumin cross-linked hydrogels, 816  
peptidase inhibitors, enkephalin, 1099  
peptide degeneration, 530  
peptide degradation, chemical pathways, 593, 703, 787  
peptide delivery, pulmonary, 565  
peptide drug absorption, 308  
peptide prodrugs, 885  
percolation theory, 113, 893  
percolation threshold, 893  
percutaneous absorption, acyclovir, 64  
percutaneous absorption, benzoic acid, 1147  
percutaneous absorption, 673  
percutaneous absorption, antiinflammatory ointment, 1152  
percutaneous absorption, benzoic acid, 230  
percutaneous absorption, benzoic acid, 352  
percutaneous absorption, estradiol, 170  
percutaneous absorption, lidocaine, 1033  
percutaneous absorption, mathematical model, 230  
percutaneous absorption, p-aminobenzoic acid, 1147  
percutaneous absorption, salicylate, 762  
percutaneous absorption, solvent vehicle effect, 64  
percutaneous absorption, steroids, 1320  
percutaneous drug delivery, acyclovir, 64  
percutaneous penetration, shed snake skin, in vitro, 1042  
periodontal disease, sustained release drug delivery, 313  
permeability, percutaneous, 1302  
permeation enhancer, *N*-decylmethylsulfoxide, 34  
permeation enhancer, nasal mucosa, 468  
Peyer's patches, particle absorption, 848  
pH rate profile, gonadorelin stability, 1253  
pH-sensitive liposomes, cytoplasmic delivery, 824  
pharmacodynamics, estradiol, 1107  
pharmacodynamics, phenylpropanolamine, urine pH, 96  
pharmacodynamics, apomorphine, 318  
pharmacodynamics, estradiol prodrug, 1011  
pharmacodynamics, percutaneous lidocaine, 1033  
pharmacokinetic models, human nasal cavity, 69  
pharmacokinetic profile, 677  
pharmacokinetic screening *o*-quinone analogues, 1071  
pharmacokinetics acetaminophen, 204  
pharmacokinetics antipyrine, 204  
pharmacokinetics beta-cyclodextrin, 1248  
pharmacokinetics carbamazepine, 513  
pharmacokinetics DGA VP, vasopressin analog, 293  
pharmacokinetics ganciclovir, 1113  
pharmacokinetics gentamicin, anesthetized rat, 41  
pharmacokinetics gentamicin, conscious rat, 41  
pharmacokinetics imirestat, ocular, 192  
pharmacokinetics methylergometrine, rat, 14  
pharmacokinetics phenylpropanolamine, urine pH, 97  
pharmacokinetics, antimicrobial drugs in otitis media, 1242  
pharmacokinetics, apomorphine, 318  
pharmacokinetics, bismuth, 237  
pharmacokinetics, chimeric monoclonal antibody (C-17-1A), 587  
pharmacokinetics, clozapine, 347  
pharmacokinetics, diazepam, phenytoin, ACC-9653, interaction, 1172  
pharmacokinetics, diltiazem, 874  
pharmacokinetics, estradiol, 879  
pharmacokinetics fleroxacin, 422  
pharmacokinetics, hydralazine, 274  
pharmacokinetics, hydroxy-beta-cyclodextrin, 1248  
pharmacokinetics, linear reversible metabolic systems, 628  
pharmacokinetics, lithium carbonate, 359  
pharmacokinetics, MRT, 103  
pharmacokinetics, nadolol, 953  
pharmacokinetics, pafenolol, 1222  
pharmacokinetics, zidovudine, 411  
pharmacokinetics, zidovudine, rabbit, 332  
phase diagrams, 683  
phenobarbital *N*-beta-D-glucoside, absolute configuration, 402  
phenobarbital, kinetics of effect in renal failure, 242  
phenol derivatives, insulin binding, 600  
phenyl acetic acid, derivative anticholinergic, 746  
phenylephrine, ocular pharmacokinetics, 476

- phenylpropanolamine, pharmacodynamics, pharmacokinetics, 96  
phenylpropanolamine, HPLC, 96  
phenytoin, prodrug, 1172  
phosphatidylserine binding to imipramine, 1019  
phosphatidylserine binding to propranolol, 1019  
phosphatidylserine binding to quinidine, 1019  
phthalate dialkyl esters, parenteral product, 911  
phthalates source in packaging materials, 178  
physical aging, hydroxypropyl methylcellulose phthalate, 648  
plasma protein binding of drugs, microdialysis, 1077  
plasma-catalyzed hydrolysis, TRH, 751  
polarography, oxygen, stability testing, 289  
poly(DL-lactic acid-co-glycolic acid), phase separation, 928  
poly(lactide-co-glycolide), 1190  
poly(vinylpyrrolidone (PVP)), 654  
poly-(2-hydroxyethyl)-aspartamides, aerosols, rat, 990  
polydimethylsiloxane membranes, 523  
polyelectrolytes, 491  
polyelectrolytes, physical aging, 648  
polyethylene glycol, compactibility, 113  
polyethylene glycol, gastrointestinal absorption, 863  
polyethylene glycol, nasal absorption enhancer, 808  
polyethylene glycol, nasal absorption, 863  
polyethylene terephthalate (PET) amber bottle, 176  
polymer bioadhesive strength, 491  
polymer drugs, 852  
polymer swelling, 523  
polymer-solvent affinity, 928  
polymers, pulmonary absorption, 990  
polyolefin/solute interactions, 911  
polyoxyethylene 9 lauryl ether, nasal absorption enhancer, 808  
polypeptides, lung absorption, 990  
porosity, polymer matrix, 893  
powder systems, binary, 113  
preformulation lipophilicity screen, 577  
preservatives, insulin, 600  
pressurized inhaler, particles size analysis, 1228  
primaquine metabolism, 91  
primaquine, deuterium isotope effect, 91  
probenecid, distribution enhancer, AZT, 332  
probenecid, effect on disposition, AZT, 411  
prodrug phenylephrine oxazolidine, 476  
prodrug, estradiol, 1061  
prodrug, phenytoin, 1172  
prodrug, zidovudine, 948  
prodrugs, TRH, 885  
products inhibition hydrolase, 251  
progesterone release, 1195  
progesterone, beta-cyclodextrin complex, 869  
propranolol, liposomes, 957  
propranolol, tissue distribution, 1019  
propylene glycol water mixture, heat sterilization, 1273  
propylene glycol, heat sterilization, 1273  
protease inhibitor, wound healing, 1289  
protein aggregation, lyophilization, 1086  
protein binding, bismuth, 188  
protein binding, methylgometrine, 14  
protein binding, milk, 633  
protein binding, moxalactam, 364  
protein binding, pyrimethamine, 1055  
protein binding, valproic acid, 461  
protein conjugation, neocarzinostatin, 852  
protein release, 1190  
protein stability, 1190  
protein-hapten conjugate, 767  
proteinases, inhibitors, 430  
pulmonary absorption, polymers, 990  
pulmonary barrier, aerosol absorption, 8  
pulmonary bioavailability, terbutaline, 1068  
pulmonary delivery, peptide, 565  
purines, intestinal absorption, 299  
puromycin, peptidase inhibitors, 1099  
pyrimethamine, HPLC, 1055  
pyrimethamine, plasma protein binding, 1055  
QSAR anticholinergic, 746  
quantitative structure-activity relationship (QSAR) index, 801  
quantitative structure-activity relationships (QSAR), liposomes, 508  
quasi-equilibrium, drug dissolution, 425  
quinidine, tissue distribution, 1019  
quinones, antifungal agents, 283  
racemic mixtures, 683  
radiotelemetric technique, enteric coated formulation, 1026  
receptors, alpha-2 adrenergic, 208  
receptors, cholinergic, 563  
rectal absorption, insulin, 180  
rectal administration, L-dopa, L-dopa esters, 384  
rectum, insulin, 180  
red blood cell, bismuth, 188  
redox drug delivery, estradiol, 879  
reductase enzyme, prodrug activation, 723  
reduction potentials, antifungal agents, 282  
reimbursement for drug, 108  
release profile, theophylline, 1167  
remoxipride, <sup>111</sup>In marked spheres, 54  
remoxipride, extended release, 54  
remoxipride, oral absorption, 54  
renal clearance, phenylpropanolamine, 96  
renal clearance, sulfate, 719  
renal failure, kinetics of drug action, 242  
renal secretion, ganciclovir, 1113  
renin inhibitory peptide, activity assay, 407  
renin inhibitory peptides, human, 407  
resistance, electrical, skin, 213, 222  
respirable fraction, leuprolide, 565  
retarded release, methacrylate-salicylic acid, 1208  
reversible metabolism, 628, 1003  
reversible metabolism, mean residence time, 103  
rheological method, mucin-biopolymer bioadhesion, 491  
ribonuclease A, freeze dried, stability, 1086  
rolipram, percutaneous absorption, 1302  
rotating dialysis cell, theophylline, 1134  
rotating disk method, 80  
RS-26306, luteinizing hormone-releasing hormone antagonist, 530  
salicylate, skin permeation, 762  
salicylic acid, retarded release, 1208  
sarafloxacin, HPLC, 1177  
scaling laws, 893  
scanning electron micrography, 264  
scanning electron microscopy, misoprostol films, 1181  
scanning electron microscopy, nasal mucosa, 468  
scintigraphy, <sup>18</sup>F-imirestat, 1181  
scintigraphy, ibuprofen, 304  
second messengers, 1213  
sesquiterpene lactones, *Michelia floribunda*, 1269  
shed snake skin, skin penetration, 1042  
shelf life, vitamin A, 388  
shelf-life prediction, aspirin, 730  
silymarin, antihepatotoxins, 256  
simvastatin stability testing, 289  
site and stereospecific drug delivery, 723  
skin absorption, iontophoresis, 118  
skin absorption, rolipram, 1302  
skin absorption, salicylate, 762  
skin blood flow, isosorbide dinitrate, 1298  
skin human, estradiol absorption, 170  
skin human, iontophoresis, 134  
skin penetration, 1302  
skin penetration, total reflectance IR, 835  
skin permeation technique, in vitro, 995  
skin permeation, azidothymidine, 34  
skin permeation, fatty acids, 712  
skin permeation, isosorbide dinitrate, 1298  
skin permeation, zidovudine, 948  
skin sandwich flap, human, 352  
skin sandwich flap, in vivo, 352

- skin, hairless mouse, 118, 213, 222  
 skin, human allograft, 1141  
 skin, human, percutaneous absorption, 230  
 skin, metabolism, 1099  
 skin, partition coefficient, 230  
 skin, permeation enhancing, 621  
 skin fetal, pig, 1201  
 slow release tablet diclofenac, 1026  
 smancs, oral administration, 852  
 snake skin, model membrane, 1302  
 sodium glycolate, nasal absorption enhancer, 127, 370, 808  
 sodium ion transport, human skin, 134, 1141  
 sodium lauryl sulfate, nasal absorption enhancer, 808  
 sodium tauro-24, 25-dihydrofusidate, insulin rectal absorption enhancer, 180  
 sodium taurodihydrofusidate (STDHF), nasal absorption enhancer, 144  
 sodium taurodihydrofusidate (STDHF), permeation enhancer, 547  
 solid-state nuclear magnetic resonance (NMR), carbamazepine, 184  
 solubility benzocaine, 523  
 solubility of drugs in milk, 537  
 solubility, 942  
 solubilization, liposomes, 957  
 solubilizers, cyclodextrins, 612  
 solute migration, polymers, 967  
 solutions ideal, 1157  
 solvent drag, skin permeation, 712  
 solvent, permeation skin, 712  
 spermatogenesis, 1  
 stability gonadorelin, aqueous solution, 1253  
 stability indomethacin, 484  
 stability prediction, vitamin A preparation, 388  
 stability testing, simvastatin, 289  
 stability testing, lovastatin, 289  
 stability triptorelin, aqueous solution, 1253  
 stability, ACTH, 593  
 stability, asparaginyl peptides, 703  
 stability, insulin, 600  
 stability, LH-RH antagonist, 530  
 stability, methotrexate, in vitro, 418  
 stability, monoclonal antibody, 1234  
 stability, pentostatin, 452  
 stability, solid state misoprostol, 1186  
 stability, vidarabine in nanocapsules, 736  
 steady state drug concentration, 677  
 stereochemistry amobarbital N-glucosides, 794  
 stereospecific reduction, beta-adrenergic prodrug, 723  
 sterilization heat, thermodynamic data, 1273  
 steroids, complexation/beta-cyclodextrin, 869  
 steroids, percutaneous absorption, 1320  
 stratum corneum, 762  
 stratum corneum, fetal skin, 1201  
 stratum corneum, permeability, 621  
 stratum corneum, steroid penetration, 1320  
 stratum corneum, total reflectance IR, 835  
 stratum corneum, Yucatan pig, mouse, human, 673  
 striatum, rat, dopamine receptor, 280  
 subcutaneous administration, lymphatic absorption, 167  
 sucrose, rubbery state, 1278  
 sufentanyl, transdermal delivery, 842  
 sulfamethoxazole, pharmacokinetics middle ear, 1242  
 sulfanilic acid protein conjugate, 767  
 sulfanilic acid, intestinal transport, 767  
 sulfate homeostasis, 719  
 sulfate, effect of chronic aspirin administration, humans, 719  
 superoxide, 260  
 surface response modeling, matrix tablet, 1092  
 surfactant, fluorescein, rat lung absorption, 8  
 surfactant, permeation enhancer, 468  
 sustained release ibuprofen, 303  
 sustained-release delivery system, dental diseases, 313  
 sustained-release lithium carbonate, in vitro, in vivo, 359  
 swelling controlled release, 431  
 swelling ration, hydrogel, 816  
 symmetry, molecular, 942  
 tablet filler, dissolution rates, 80  
 tablets, content uniformity, 962  
 tablets particle size, 962  
 tachycardia arrhythmia, lidocaine, 28  
 tachycardia, ouabain induced, 28  
 tauro-24,25-dihydrofusidate sodium, 547  
 taurocholate, influence on intestinal absorption of drugs, 392  
 temafloxacin, HPLC, 1177  
 temperature sensitive icebergs, 730  
 tenoxicam, binding to casein, 633  
 terbutaline, pulmonary bioavailability, 1068  
 terbutaline sulfate, metered dose inhaler, 1068  
 tertiary basic drugs, effect on mitochondrial activity, 398  
 testosterone, beta-cyclodextrin complex, 869  
 tetracycline, sustained release, 313  
 tetrahydroacridine, brain targeted derivative, 658  
 theophylline, controlled release, 1134  
 theophylline, in vitro-in vivo, 1167  
 theophylline, kinetics of effect in renal failure, 242  
 theophylline, sustained release, 1167  
 therapeutic index, diuretics, 697  
 thermodynamic data, heat sterilization, 1273  
 thermodynamics activation parameters, aspirin, 730  
 thermodynamics, chlorpromazine, 856  
 thermodynamics, HPLC retention, 577  
 thermodynamics, insulin ligand binding, 606  
 thermospray liquid chromatography/mass spectroscopy, arteether, 923  
 thin films, topical delivery, 1048  
 third party programs, 108  
 threo-methylphenidate, optical purity determination, 726  
 thyrotropin-releasing hormone (TRH) stability in human plasma, 751  
 thyrotropin-releasing hormone (TRH), bioreversible derivatization, 885  
 tissue concentrations, fleroxacin, 422  
 tissue distribution, basic drugs, rabbit, 691  
 tissue distribution, estradiol, 1061  
 tissue distribution, multiple drugs, 935  
 tissue distribution, quinidine, propranolol, imipramine, 1019  
 tolmetin, irreversible binding to albumin in vitro, 21  
 topical anesthesia, lidocaine, 1033  
 topical delivery, enhanced, 621  
 topical delivery, thin films, 1048  
 topical irritation, gastrointestinal tract, 616  
 topological accessibility, 801  
 toxicity, primaquine, 91  
 toxoplasmosis, 1055  
 Transderm-Nitro, Yucatan pig, 673  
 transdermal absorption, TNG, 673  
 transdermal delivery, enhancers, 621  
 transdermal delivery, enkephalin, 1099  
 transdermal delivery, narcotic analgesics, 842  
 transdermal delivery, rolipram, 1302  
 transdermal drug delivery, 111  
 transdermal enhancement, 835  
 transdermal enhancement, salicylate, 762  
 transdermal permeation, 762  
 transdermal permeation, fetal skin, 1201  
 transdermal, chlorhexidine phosphanilate, 995  
 transdermal, electroosmosis, 213, 222  
 transdermal, shed snake skin, 1042  
 transdermal, sodium ions, 1141  
 transdermal, zidovudine, 948  
 transepithelial transport, aliphatic carboxylic acids, 325  
 transference number, 213, 222  
 transmission infrared, misoprostol films, 1181  
 transport cell culture, 435  
 transport mechanism, iontophoresis, 118  
 transport, Caco-2 cell monolayers, 902  
 transport, L-alpha-methyl dopa, 1313



- transport, permeability, 902
- TRH, prodrugs, 885
- triamcinolone diacetate, bioavailability, 558
- triamcinolone, bioavailability, 558
- trimethoprim, pharmacokinetics middle ear, 1242
- triptorelin, stability, 1253
- tropic acid, derivative cholinergic, 746
- tumor targeting, macromolecules, 339
- tumorigenesis, role of cholinesterases, 1
- two-dimensional nuclear magnetic resonance (2D-NMR), arteether, 923
- tyrosine hydroxylase (TH) activity, amantidine, 670
- tyrosine, iontophoresis, 222
  
- ultraviolet absorption, captopril, 1082
- uniformity, tablets, 962
- unit impulse response methodology, DGV AP, 292
- urine alkalization, 96
- urogastrone, receptor, 665
- USP dissolution standards, 983
  
- vaccine, aluminum adjuvants, 1282
- valproic acid, binding to rat plasma, 461
- vasopressin analog, blood brain barrier, 292
  
- vesicles, multilamellar, 1127
- vidarabine-loaded nanoparticles, 736
- viscosity mucin-biopolymer, 491
- vitamin A palmitate, 388
- volume of distribution, reversible metabolism, 628
- volume/flow ratio of gastrointestinal fluids, 518
  
- Wagner-Nelson method, 76
- water of hydration, cefaclor, 147
- water sorption isotherm, misoprostol, 1186
- water vapor absorption, PVP, 654
- wax coating, 1119
- wound healing, gabexate mesilate, 1289
- wound healing, gelatin, 1289
- wound healing, nafamostat mesilate, 1289
- wound healing, protease inhibitor, 1289
  
- Yucatan Pig, Transderm-Nitro, 673
  
- z-value, heat sterilization, 1273
- zidovudine (AZT), uptake in cerebrospinal fluid, 332
- zidovudine, renal clearance, 411
- zidovudine, skin permeation, 948